Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?
about
Escalating doses of donor lymphocytes for incipient graft rejection following SCT for thalassemia.Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia.Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia.Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time.Diagnostic molecular pathology, part 2: proteomics and clinical applications of molecular diagnostics in hematopathology.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioNonmyeloablative conditioning with busulfan before matched littermate bone marrow transplantation results in reversal of the disease phenotype in canine leukocyte adhesion deficiency.Lack of utility of chimerism studies obtained 2-3 months after myeloablative hematopoietic cell transplantation for ALL.National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committeeNew frontiers in pediatric Allo-SCT.Donor Chimerism of B Cells and Nature Killer Cells Provides Useful Information to Predict Hematologic Relapse following Allogeneic Hematopoietic Stem Cell Transplantation.How and when should we monitor chimerism after allogeneic stem cell transplantation?Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?A technical application of quantitative next generation sequencing for chimerism evaluationReduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'.Philadelphia positive acute lymphoblastic leukaemia of childhood.Alternative donor transplants for adult acute lymphoblastic leukaemia: a comparison of the three major options.Cellular therapy following allogeneic stem-cell transplantation.Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment.Ciclosporin kinetics in children after stem cell transplantation.Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases.Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia.Acute GvHD: pathogenesis and classification.Advances in the treatment of acute graft-versus-host disease.Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy.Automated detection of residual cells after sex-mismatched stem-cell transplantation - evidence for presence of disease-marker negative residual cells.Acute graft-versus-host disease: are we close to bringing the bench to the bedside?The allogeneic graft-versus-cancer effect.Recent advances in quantitative chimerism analysis.Relapse after allogeneic stem cell transplantationDonor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation.Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia.Immunotherapy of invasive fungal infection in hematopoietic stem cell transplant recipients.Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation.Hematopoietic stem cell transplantation and immunotherapy for pediatric acute myeloid leukemia: an open challenge.New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL.When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia.An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy.Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia.
P2860
Q33386915-A39380AE-991E-4685-991B-A61084227664Q33831349-930311F7-8F14-4070-BBF3-ED27B29B1DADQ33886177-BE528F25-7873-4020-96FD-D0F19CF42936Q33905443-389110D5-5FEE-4459-8D12-C3E756324BD6Q33945053-71E592F1-2AE8-49EB-B27C-F5E05C508EDEQ34202277-E53FCC1C-D0BB-4E18-ACF5-D5E49FD07872Q34314268-ADF542D6-0712-4697-9210-F33D835D56D5Q34600830-3D516282-CC8B-4FA5-96CD-B2E5DF6548A5Q35008021-3DA743CF-89A7-416A-897F-EA054B59EBF0Q35628739-8270DE01-D606-49F5-8ADC-3B54B772D725Q35726470-CD1519A4-9E2C-490F-BE8D-2BB10183C687Q35926907-AF85067B-514E-47B6-8D10-5F276649040BQ36069886-9FA6EFBF-A78B-45EF-B525-7BFAFEB8B129Q36097066-647DBDDD-93F2-4304-B061-3920DDE97A50Q36182976-66648ED4-6845-4891-8D17-A55A6CD9ABC1Q36228062-6FA9F877-2856-42E4-B802-6CCEB5CBE969Q36557963-52D81757-74F4-462B-BA49-A5BDCFF141A6Q36612643-57193F07-B625-47BE-B567-CD7E08DB5116Q36861714-7E698C16-6514-4123-9E1D-E49034271F98Q36922221-8125AA69-D4D5-43B2-9C98-3A419490C75FQ37014122-7CA23525-B0F4-47C5-9182-58D479CB9F29Q37148120-F6C72A2B-004C-49E6-971D-628EF8431617Q37188484-A98ACE7E-0720-4AEB-9506-587BCEB13AA9Q37191057-8D3A637F-6EFB-4216-8EAA-BF15B36A8115Q37216272-582FAA4D-E490-4A9B-B075-1184E083E2E0Q37227738-3E3F5857-1CBD-4492-8F23-D1A02C6D35CDQ37402799-49A439BC-68D5-4605-9B7D-742F4CBB649DQ37593125-66946D14-04BD-4235-9D21-A47A97B41B1EQ37628681-20AD2E3B-C86C-4C68-86BA-0D063F22493DQ37810125-78883DD6-784F-4AD1-ABF7-8D1670F37C90Q37832506-76C5D750-5500-4506-8138-C7631FA37768Q37905034-0A4CA8EC-0F2F-452C-9122-20F6A9F37BB0Q38028808-ACDCA946-9265-419A-8728-FCB3966E978AQ38081105-273F7373-FD8D-49A1-8698-61F44234D624Q38105123-621AD94C-9C13-4B83-8114-AED9E0F312A4Q38195065-E951C7E2-A5C6-4B4B-8043-34B83C9F003FQ38220573-416CB2C9-2535-4448-AAB4-F5457C838D5DQ39420711-BA991B50-3E0F-4385-8E08-2B514FE16497Q39704843-7C13421B-B162-4C09-A0D1-5BB4B0BBB024Q39712243-85772F5C-9A7D-4CDE-BE21-6F512BEF6E5E
P2860
Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Increasing mixed chimerism is ...... for pre-emptive immunotherapy?
@en
Increasing mixed chimerism is ...... for pre-emptive immunotherapy?
@nl
type
label
Increasing mixed chimerism is ...... for pre-emptive immunotherapy?
@en
Increasing mixed chimerism is ...... for pre-emptive immunotherapy?
@nl
prefLabel
Increasing mixed chimerism is ...... for pre-emptive immunotherapy?
@en
Increasing mixed chimerism is ...... for pre-emptive immunotherapy?
@nl
P2093
P50
P356
P1476
Increasing mixed chimerism is ...... for pre-emptive immunotherapy?
@en
P2093
Arend Von Stackelberg
Bernd Gruhn
Bernhard Kremens
Charlotte Niemeyer
Dagmar Dilloo
Dietrich Niethammer
Gregor Dueckers
Günter Henze
Hermann Kreyenberg
James F Beck
P304
P356
10.1200/JCO.2004.05.198
P407
P577
2004-05-01T00:00:00Z